Evaluation of the effect of therapeutic plasma exchange on serum cytokine levels in pediatric intensive care unit.

Ther Apher DialJan 4, 2025 (epub)
Clinical ResearchPediatricsOpen access

Selen Ceren Cakmak, Hazal Ceren Tugrul, Dilan Akgun Unlu et al.

✦ AI-curated · Sources linked

In 30 seconds

This clinical study assessed changes in serum IL-6 and TWEAK in 41 critically ill children in a pediatric intensive care unit who underwent therapeutic plasma exchange (TPE) between May and December 2022. Measurements before and after the procedure showed that IL-6 increased significantly after TPE (p: 0.006), whereas TWEAK decreased (p: 0.030). Pre-TPE levels of these markers were associated with selected measures of illness severity, but neither marker differed significantly by prognosis. The findings suggest potential value for assessing inflammation and severity, but not for predicting outcome.

Key findings

  • IL-6 levels rose significantly after TPE (p: 0.006), while TWEAK levels fell (p: 0.030).
  • Pre-TPE IL-6 correlated positively with ventilation duration and ferritin levels (p <0.05).
  • Pre-TPE TWEAK correlated with organ failure indicators and D-Dimer levels (p <0.05).
  • IL-6 and TWEAK levels did not differ significantly by prognosis (p >0.05).

Why it matters

The opposing post-procedure changes show that cytokine measurements may be affected by TPE itself, which is relevant when interpreting serial results in critically ill children. Associations with severity indicators may support their use as markers of inflammation or illness burden, but the absence of a prognostic difference cautions against treating these measurements as reliable outcome predictors.

What to keep in mind

The study observed a small group of 41 children undergoing TPE and reports pre- and post-procedure measurements; it does not establish that the cytokine changes were caused by TPE or that the markers predict clinical outcomes.

Source

Published in Ther Apher Dial. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.